Masaomi Iyo Selected Research

Dopamine (Intropin)

7/2022	Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis: A 6-Year Retrospective Comparative Study.
12/2021	Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state rats.
12/2021	Interacting Roles of COMT and GAD1 Genes in Patients with Treatment-Resistant Schizophrenia: a Genetic Association Study of Schizophrenia Patients and Healthy Controls.
6/2021	Genetic risks of schizophrenia identified in a matched case-control study.
1/2021	Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after continuous administration of haloperidol.
1/2021	Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.
1/2021	Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats.
1/2021	Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity.
11/2020	The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.
10/2020	A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masaomi Iyo Research Topics

Disease

105	Schizophrenia (Dementia Praecox) 07/2022 - 02/2002
71	Psychotic Disorders (Schizoaffective Disorder) 07/2022 - 02/2002
24	Treatment-Resistant Schizophrenia 10/2022 - 09/2012
16	Cognitive Dysfunction 03/2022 - 05/2004
13	Tardive Dyskinesia 12/2021 - 10/2002
13	Major Depressive Disorder (Major Depressive Disorders) 01/2021 - 07/2003
13	Feeding and Eating Disorders (Eating Disorder) 02/2017 - 08/2003
12	Alzheimer Disease (Alzheimer's Disease) 02/2019 - 04/2002
11	Bipolar Disorder (Manic Depressive Psychosis) 01/2022 - 05/2004
10	Mental Disorders (Mental Disorder) 08/2011 - 07/2003
7	Substance-Related Disorders (Drug Abuse) 03/2008 - 10/2004
6	Anorexia Nervosa 02/2017 - 08/2003
6	Bulimia Nervosa 02/2017 - 08/2003
5	Mood Disorders (Mood Disorder) 01/2021 - 01/2004
4	Disease Progression 01/2022 - 06/2009
4	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021 - 10/2007
4	Weight Gain 03/2020 - 08/2006
4	Dementia (Dementias) 01/2015 - 01/2013
4	Panic Disorder (Panic Attack) 10/2007 - 06/2004
3	Sleepiness 04/2021 - 01/2013
3	Body Weight (Weight, Body) 01/2021 - 08/2006
3	Mania (Manias) 01/2020 - 02/2004
3	Genetic Predisposition to Disease (Genetic Predisposition) 01/2020 - 08/2010
3	Movement Disorders (Movement Disorder) 01/2017 - 06/2015
3	Autistic Disorder (Autism) 11/2007 - 12/2006
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2022 - 01/2013
2	Type 2 Diabetes Mellitus (MODY) 09/2021 - 01/2013
2	Psychomotor Agitation (Akathisia) 04/2021 - 06/2019
2	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2021 - 06/2013
2	Autism Spectrum Disorder 01/2021 - 01/2017
2	Social Phobia 01/2016 - 01/2013
2	Treatment-Resistant Depressive Disorder 01/2016 - 01/2005
2	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2014 - 07/2002

Drug/Important Bio-Agent (IBA)

43	Antipsychotic Agents (Antipsychotics)IBA 07/2022 - 02/2002
39	Methamphetamine (Desoxyn)FDA LinkGeneric 08/2015 - 09/2002
37	Dopamine (Intropin)FDA LinkGeneric 07/2022 - 10/2004
19	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2022 - 02/2002
19	Brain-Derived Neurotrophic Factor (BDNF)IBA 02/2017 - 07/2003
18	Pharmaceutical PreparationsIBA 01/2022 - 06/2003
14	N-Methylaspartate (NMDA)IBA 01/2022 - 02/2002
14	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2003
11	Serine (L-Serine)FDA Link 06/2015 - 06/2003
9	Aripiprazole (Abilify)FDA Link 01/2021 - 05/2012
9	Risperidone (Risperdal Consta)FDA LinkGeneric 09/2019 - 06/2010
7	Proteins (Proteins, Gene)FDA Link 12/2015 - 07/2003
6	Clozapine (Clozaril)FDA LinkGeneric 08/2021 - 02/2003
6	Biological ProductsIBA 01/2021 - 06/2005
6	EnzymesIBA 03/2011 - 09/2002
6	Glutamic Acid (Glutamate)FDA Link 03/2011 - 02/2002
6	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 08/2010 - 04/2002
6	Glycine (Aminoacetic Acid)FDA LinkGeneric 06/2008 - 02/2002
5	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 07/2022 - 06/2013
5	Lurasidone Hydrochloride FDA Link 04/2021 - 06/2019
5	Fluvoxamine (Luvox)FDA LinkGeneric 10/2012 - 03/2007
5	Phencyclidine (Angel Dust)IBA 01/2012 - 02/2002
5	Glutathione (Reduced Glutathione)IBA 01/2009 - 02/2002
4	Oxytocin (Pitocin)FDA LinkGeneric 10/2022 - 08/2015
4	gamma-Aminobutyric Acid (GABA)IBA 03/2022 - 01/2021
4	ProlactinIBA 01/2021 - 08/2014
4	Olanzapine (Zyprexa)FDA Link 10/2020 - 05/2012
4	Donepezil (Aricept)FDA LinkGeneric 02/2019 - 12/2005
4	Haloperidol (Haldol)FDA LinkGeneric 10/2017 - 06/2004
4	Antidepressive Agents (Antidepressants)IBA 01/2016 - 07/2003
4	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2016 - 10/2007
4	Sigma-1 ReceptorIBA 10/2012 - 03/2007
4	Tropisetron (Navoban)IBA 12/2011 - 07/2005
3	ifenprodilIBA 01/2022 - 06/2004
3	blonanserinIBA 04/2021 - 12/2016
3	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 01/2021 - 07/2014
3	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2020 - 02/2014
3	Dopamine Receptors (Dopamine Receptor)IBA 01/2017 - 06/2009
3	D-Amino-Acid Oxidase (D-Amino Acid Dehydrogenase)IBA 06/2015 - 06/2005
3	Serotonin (5 Hydroxytryptamine)IBA 03/2011 - 06/2008
3	Glutamine (L-Glutamine)FDA Link 06/2010 - 01/2005
3	AntioxidantsIBA 01/2009 - 02/2002
3	DNA (Deoxyribonucleic Acid)IBA 10/2008 - 09/2002
2	OrexinsIBA 01/2022 - 08/2015
2	Valproic Acid (Depakote)FDA LinkGeneric 08/2021 - 01/2020
2	AcidsIBA 01/2021 - 03/2006
2	LithiumIBA 01/2021 - 01/2005
2	Homovanillic AcidIBA 01/2021 - 01/2020
2	Paliperidone Palmitate FDA Link 01/2020 - 01/2019
2	Messenger RNA (mRNA)IBA 01/2018 - 07/2003
2	BenzodiazepinesIBA 01/2016 - 11/2010
2	beta-Arrestin 1IBA 12/2015 - 01/2015
2	G-protein-coupled receptor kinase 6IBA 12/2015 - 01/2015
2	Milnacipran (Ixel)FDA Link 01/2015 - 01/2005
2	Yi-Gan SanIBA 01/2015 - 01/2015
2	Therapeutic UsesIBA 03/2013 - 02/2003
2	serine racemaseIBA 01/2013 - 06/2005
2	Cholinergic ReceptorsIBA 12/2011 - 02/2007
2	A-factor (Streptomyces)IBA 03/2011 - 07/2006
2	Purinergic P1 Receptors (Adenosine Receptor)IBA 03/2011 - 08/2010

Therapy/Procedure

11	Therapeutics 04/2021 - 06/2005
7	Drug Therapy (Chemotherapy) 07/2016 - 12/2011
6	Injections 07/2022 - 04/2013
4	Kampo Medicine (Kampo) 01/2014 - 02/2011
3	Aftercare (After-Treatment) 03/2013 - 06/2005
2	Transcranial Magnetic Stimulation 01/2021 - 01/2016
2	Secondary Prevention 10/2013 - 09/2012